Q4 2025 IDEXX Laboratories Inc Earnings Call Transcript
Key Points
- IDEXX Laboratories Inc (IDXX) reported a 14% increase in revenue for Q4 2025, with 12% organic growth, driven by strong performance in CAG Diagnostics recurring revenues.
- The company achieved record premium instrument placements in Q4, with over 1,900 IDEXX inVue Dx placements, contributing to a 69% organic year-over-year expansion in CAG Diagnostic instrument revenues.
- Full year operating margins improved to 31.6%, an increase of 90 basis points, supported by solid revenue expansion and productivity gains.
- IDEXX Laboratories Inc (IDXX) reported a full year EPS of $13.08, up 14% year-over-year, driven by strong operational performance.
- The company successfully launched new innovations like inVue Dx and Cancer DX, creating a solid foundation for future growth and supporting a 200 basis points overall company growth.
- Pressure on clinical visits remains a headwind, with US same-store clinical visit declines of approximately 1.7% in Q4 and 1.9% for the full year 2025.
- Wellness and discretionary visits are more pressured than sick patient visits, with wellness visits down 3.6% in Q4.
- Rapid assay revenues declined 3% on an organic basis in Q4, constrained by pressure on US wellness visits and transition of pancreatic lipase to Catalyst slide.
- The company anticipates declines in CAG instrument revenues in 2026 as they lap the rapid expansion of IDEXX inVue Dx instrument placements.
- IDEXX Laboratories Inc (IDXX) is planning for a 2% decline in US same-store clinical visit growth in 2026, reflecting ongoing macro and sector constraints.
Good morning, and welcome to the IDEXX Laboratories fourth quarter 2025 earnings conference call. As a reminder, today's conference is being recorded. Participating in the call this morning are Jay Mazelsky, President and Chief Executive Officer; Andrew Emerson, Chief Financial Officer; and John Ravis, Vice President, Investor Relations.
IDEXX would like to preface the discussion today with a caution regarding forward-looking statements. Listeners are reminded that our discussion during the call will include forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those discussed today.
Additional information regarding these risks and uncertainties is available under the forward-looking statements notice in our press release issued this morning as well as in our periodic filings with the Securities and Exchange Commission, which can be obtained from the SEC or by visiting the Investor Relations section of our website, idexx.com.
During this call, we will be discussing certain financial measures not prepared
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
